Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470437 | 0.89 | MEN1 (0.57) | MTNR1AMTNR1BNPC1ALDH1A1MAPT | |
| SCHEMBL9361264 | 0.85 | MAPT (0.53) | CYP1A2CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15211714 | 0.84 | HSD17B10 (0.45) | MTNR1AMTNR1BCYP1A2CYP2C19NPC1 | |
| SCHEMBL5708195 | 0.84 | MEN1 (0.52) | MTNR1AMTNR1BNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5444064 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BCYP1A2NPC1RAB9A | |
| SCHEMBL9979560 | 0.84 | LMNA (0.45) | MTNR1AMTNR1BCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL10471359 | 0.82 | MTNR1A (0.50) | MTNR1AMTNR1BLMNA | |
| SCHEMBL10222071 | 0.81 | CYP1A2 (0.59) | MTNR1AMTNR1BCYP1A2NPC1RAB9A | |
| SCHEMBL16160333 | 0.81 | MTNR1A (0.62) | MTNR1AMTNR1BCYP1A2NPC1RAB9A | |
| SCHEMBL20309078 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BCYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1620086-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION | Warner-Lambert Company LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-26 | — | — | US | disclosed |
| US-6875780-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-6867224-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004091604-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | BRATTON LARRY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARG, PPARD | MTNR1A 288/4885MTNR1B 270/4885CYP1A2 2064/4885 |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | MTNR1A 327/4885MTNR1B 258/4885CYP1A2 1598/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | MTNR1A 327/4885MTNR1B 258/4885CYP1A2 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.